CELLAVISION AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 224.5 SEK | +2.05% |
|
+1.35% | +5.90% |
| Feb. 07 | Transcript : CellaVision AB, Q4 2023 Earnings Call, Feb 07, 2024 | |
| Feb. 07 | CellaVision AB Proposes Dividend for the Year 2023 | CI |
| Sales 2024 * | 779M 71.4M | Sales 2025 * | 889M 81.44M | Capitalization | 5.35B 490M |
|---|---|---|---|---|---|
| Net income 2024 * | 174M 15.94M | Net income 2025 * | 218M 19.97M | EV / Sales 2024 * | 6.72 x |
| Net cash position 2024 * | 117M 10.72M | Net cash position 2025 * | 208M 19.07M | EV / Sales 2025 * | 5.79 x |
| P/E ratio 2024 * |
30.9
x | P/E ratio 2025 * |
24.5
x | Employees | - |
| Yield 2024 * |
1.1% | Yield 2025 * |
1.23% | Free-Float | 61.96% |
More Fundamentals
* Assessed data
More news
Latest transcript on CellaVision AB
More press releases
| 1 day | +2.05% | ||
| 1 week | +1.35% | ||
| Current month | -6.07% | ||
| 1 month | -3.02% | ||
| 3 months | +12.47% | ||
| 6 months | +82.82% | ||
| Current year | +5.90% |
1 week
214.50
225.00
1 month
212.50244.00
Current year
185.20275.00
1 year
120.00275.00
3 years
120.00503.50
5 years
120.00503.50
10 years
20.30503.50
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 59 | 94-11-15 | |
Simon Ostergaard
CEO | Chief Executive Officer | 53 | 21-03-20 |
Magnus Blixt
DFI | Director of Finance/CFO | 58 | 13-05-01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | 59 | 94-11-15 | |
Lotta Jarleryd
BRD | Director/Board Member | 58 | 22-05-10 |
Mikael Worning
CHM | Chairman | 62 | 20-04-22 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 224.5 | +2.05% | 6,409 |
| 24-04-18 | 220 | +0.69% | 4,457 |
| 24-04-17 | 218.5 | -1.35% | 7,224 |
| 24-04-16 | 221.5 | +2.07% | 9,793 |
| 24-04-15 | 217 | -2.03% | 7,887 |
Delayed Quote Nasdaq Stockholm, April 19, 2024 at 11:29 am EDT
More quotes
CellaVision AB is a Sweden-based company active in the medical technology sector. The Company develops and sells digital solutions for medical microscopy, as well as products enabling blood cell analysis and morphology diagnosis. CellaVision ABâs product portfolio consists of analyzers for automated medical microscopy analysis and software applications designed for remote access, competency testing and education. The analyzers include such brands as CellaVision DM96 and CellaVision DM1200, whereas the software applications are divided into CellaVision Body Fluid Application, CellaVision Remote Review Software and CellaVision Competency Software, among others. The Company operates four subsidiaries, based in Sweden, Canada, the United States and Japan. In June 2014, CellaVision AB acquired technology platform from Clear Lake Medical Foundation.
Calendar
2024-04-25
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
224.5
SEK
Average target price
257.5
SEK
Spread / Average Target
+14.70%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +5.90% | 480M | |
| -46.92% | 2.56B | |
| +7.27% | 1.66B | |
| -15.17% | 1.45B | |
| +18.55% | 1.2B | |
| -15.69% | 978M | |
| -24.43% | 875M | |
| -9.20% | 698M | |
| -17.12% | 687M | |
| -.--% | 301M |
- Stock Market
- Equities
- CEVI Stock
